이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MAIA Biotechnology 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Vlad Vitoc

최고 경영자

US$1.4m

총 보상

CEO 급여 비율	33.1%
CEO 임기	no data
CEO 소유권	4.3%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Vlad Vitoc 의 보수는 MAIA Biotechnology 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$24m
Dec 31 2023	US$1m	US$473k	-US$20m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$1m	US$443k	-US$16m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$703k	US$265k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Dec 31 2020	US$1m	US$75k	-US$7m

보상 대 시장: Vlad 의 총 보상 ($USD 1.43M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Vlad 의 보상이 증가했습니다.

CEO

Vlad Vitoc (54 yo)

no data

테뉴어

US$1,430,757

보상

Dr. Vlad Vitoc, MD., MBA., is the Co-founder, Chairman, President and Chief Executive Officer of MAIA Biotechnology, Inc. Dr. Vitoc is a well-seasoned biotech executive with a broad array of experience acr...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vlad Vitoc	Co-Founder	no data	US$1.43m	4.26% $ 2.7m
Ngar Louie	Independent Director	4.4yrs	US$90.00k	4.88% $ 3.0m
Jerry Shay	Chairman of Scientific Advisory Board	3yrs	데이터 없음	데이터 없음
Steven Chaouki	Independent Director	3yrs	US$60.00k	0.37% $ 232.0k
Ramiro Guerrero	Independent Director	no data	US$60.00k	1.34% $ 834.2k
Cristian Luput	Independent Director	no data	US$60.00k	1.54% $ 958.8k
Stan Smith	Lead Independent Director	no data	US$75.00k	4.2% $ 2.6m
David Ashley	Member of Scientific Advisory Board	3yrs	데이터 없음	데이터 없음
Tudor Ciuleanu	Member of Scientific Advisory Board	3yrs	데이터 없음	데이터 없음
Z. Dikmen	Member of Scientific Advisory Board	3yrs	데이터 없음	데이터 없음
Adam Yopp	Member of Scientific Advisory Board	3yrs	데이터 없음	데이터 없음
Jean-Manasse Theagene	Independent Director	1.5yrs	US$47.50k	0% $ 0

3.0yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: MAIA 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

MAIA Biotechnology 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

Lead Independent Director recently bought US$300k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

New major risk - Financial position

Maia Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Maia Biotechnology Reveals New Clinical Data Showing Thio’s Strong Efficacy in Non-Small Cell Lung Cancer

New major risk - Share price stability

MAIA Biotechnology, Inc. announced a financing transaction

MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. announced that it expects to receive $1.327985 million in funding

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC

MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $1.445 million.

MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

NYSE American Believes MAIA Biotechnology Not in Compliance with Listing Standards

MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

MAIA Biotechnology, Inc. Announces Potent Anticancer Activity of THIO in Gliomas

MAIA Biotechnology, Inc. Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (NYSEAM:MAIA) announces an Equity Buyback for $0.8 million worth of its shares.

New major risk - Revenue and earnings growth

MAIA Biotechnology, Inc. Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Reports Updates on Preliminary Survival Data for Thio-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Files Second Patent for New Telomere-Targeting Molecules Program

Lead Independent Director recently bought US$300k worth of stock

MAIA Biotechnology, Inc. Announces it Intends to Initiate its Second Phase 2 Go-To-Market Trial Evaluating THIO

MAIA Biotechnology, Inc. Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Expands Phase 2 THIO-101 Trial to Europe

High number of new and inexperienced directors

MAIA Biotechnology, Inc. has completed an IPO in the amount of $10 million.

High number of new and inexperienced directors

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령